Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OBLN

Obalon Therapeutics (OBLN) Stock Price, News & Analysis

Obalon Therapeutics logo

About Obalon Therapeutics Stock (NASDAQ:OBLN)

Advanced Chart

Key Stats

Today's Range
$2.36
$2.50
50-Day Range
$2.36
$7.64
52-Week Range
$0.66
$10.77
Volume
126,096 shs
Average Volume
7.68 million shs
Market Capitalization
$23.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive OBLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Obalon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OBLN Stock News Headlines

InterWest Management Partners X, LLC's Net Worth
Obalon Therapeutics, Inc.
The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Spero Therapeutics Inc.
Renovare Environmental Inc (RENO)
See More Headlines

OBLN Stock Analysis - Frequently Asked Questions

Obalon Therapeutics, Inc. (NASDAQ:OBLN) released its earnings results on Thursday, March, 11th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.11. The business had revenue of $0.06 million for the quarter. Obalon Therapeutics had a negative net margin of 776.76% and a negative trailing twelve-month return on equity of 161.38%.

Obalon Therapeutics's stock reverse split on the morning of Thursday, July 25th 2019.The 1-10 reverse split was announced on Wednesday, July 24th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 24th 2019. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Obalon Therapeutics (OBLN) raised $75 million in an initial public offering (IPO) on Thursday, October 6th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, Canaccord Genuity and Stifel served as the underwriters for the IPO and BTIG was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Obalon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Canopy Growth (CGC), Plug Power (PLUG), NIO (NIO), NVIDIA (NVDA) and OPKO Health (OPK).

Company Calendar

Last Earnings
3/11/2021
Today
7/13/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & Medical Instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:OBLN
CIK
1427570
Fax
N/A
Employees
2
Year Founded
2008

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.33 million
Net Margins
-776.76%
Pretax Margin
N/A
Return on Equity
-161.38%
Return on Assets
-83.58%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.86
Quick Ratio
1.86

Sales & Book Value

Annual Sales
$1.59 million
Price / Sales
15.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.60 per share
Price / Book
3.97

Miscellaneous

Outstanding Shares
10,022,000
Free Float
N/A
Market Cap
$23.85 million
Optionable
Not Optionable
Beta
-1.23

Social Links

10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:OBLN) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners